Clinical studies are already underway integrating anti-PD1/PD-L1 into neo-adjuvant or adjuvant strategies for the treatment of early-stage NSCLC (e.g., NCT02504372, NCT02998528, NCT04025879, and NCT04214262). This evidence concerns the gene CD274 and non-small cell lung carcinoma.